| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Barbara Ensoli | Q21255143 |
| Fabrizio Ensoli | Q55069671 | ||
| Stefania Bellino | Q55302859 | ||
| Orietta Picconi | Q38546631 | ||
| Cecilia Sgadari | Q38546658 | ||
| Paolo Monini | Q38546673 | ||
| P2093 | author name string | Aurelio Cafaro | |
| Fausto Titti | |||
| Vittorio Francavilla | |||
| Antonella Tripiciano | |||
| Olimpia Longo | |||
| Stefano Buttò | |||
| P2860 | cites work | Design and pre-clinical evaluation of a universal HIV-1 vaccine | Q21092234 |
| Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. | Q51964201 | ||
| Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. | Q51998598 | ||
| Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy. | Q54734214 | ||
| A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption | Q56880126 | ||
| The therapeutic phase I trial of the recombinant native HIV-1 Tat protein | Q57665211 | ||
| Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat | Q22253931 | ||
| Crystal structure of HIV-1 Tat complexed with human P-TEFb | Q24634569 | ||
| HIV-1 Tat protein mimicry of chemokines | Q24644383 | ||
| The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein | Q24680024 | ||
| Tat protein induces self-perpetuating permissivity for productive HIV-1 infection | Q24683211 | ||
| A brief history of the global effort to develop a preventive HIV vaccine | Q26851165 | ||
| Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines | Q27333734 | ||
| Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers | Q27683553 | ||
| Quantifying the uncertainty in forecasts of anthropogenic climate change | Q28141336 | ||
| HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region | Q28252310 | ||
| The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation | Q28361880 | ||
| Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART | Q28476094 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein | Q31135334 | ||
| Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity | Q33220546 | ||
| Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages | Q33255758 | ||
| Human immunodeficiency virus type 1, human protein interaction database at NCBI. | Q33377381 | ||
| Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome | Q33521702 | ||
| HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality | Q33618542 | ||
| The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study | Q33864926 | ||
| Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P | Q34055475 | ||
| Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses | Q34105993 | ||
| Challenges in HIV Vaccine Research for Treatment and Prevention | Q34148683 | ||
| Immune clearance of highly pathogenic SIV infection | Q34370314 | ||
| The immune space: a concept and template for rationalizing vaccine development | Q34399762 | ||
| HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies | Q34477471 | ||
| Novel biopanning strategy to identify epitopes associated with vaccine protection | Q34579037 | ||
| Accelerating HIV-1 Vaccine Efficacy Trials | Q34580725 | ||
| HIV-1 Tat protein induces the production of IDO in human monocyte derived-dendritic cells through a direct mechanism: effect on T cells proliferation. | Q35000687 | ||
| Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy | Q35016645 | ||
| The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses | Q35040673 | ||
| Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia | Q35077039 | ||
| A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe | Q35785031 | ||
| Toxoplasmic encephalitis in AIDS. | Q35810946 | ||
| Mutual information analysis reveals coevolving residues in Tat that compensate for two distinct functions in HIV-1 gene expression | Q35868299 | ||
| HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. | Q36132728 | ||
| HIV-1 Tat triggers TGF-beta production and NK cell apoptosis that is prevented by pertussis toxin B. | Q36502262 | ||
| Human macrophages support persistent transcription from unintegrated HIV-1 DNA. | Q36511684 | ||
| Sparse production but preferential incorporation of recently produced naive T cells in the human peripheral pool | Q36579381 | ||
| HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent v | Q36864918 | ||
| Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein | Q37104090 | ||
| What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? | Q37220038 | ||
| Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate | Q37661107 | ||
| Role of HIV-1 Tat in AIDS pathogenesis: its effects on cytokine dysregulation and contributions to the pathogenesis of opportunistic infection. | Q37768630 | ||
| Therapeutic vaccines against HIV infection | Q38013505 | ||
| HIV vaccines: a brief overview. | Q38210557 | ||
| The preventive phase I trial with the HIV-1 Tat-based vaccine | Q38378021 | ||
| Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells | Q40508633 | ||
| HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity | Q40517749 | ||
| Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. | Q41335848 | ||
| Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma | Q41435232 | ||
| Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys | Q41579160 | ||
| Surface-bound Tat inhibits antigen-specific CD8+ T-cell activation in an integrin-dependent manner | Q41702127 | ||
| Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients | Q41734588 | ||
| Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. | Q41880147 | ||
| Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. | Q41925734 | ||
| HIV-1 Tat affects the programming and functionality of human CD8⁺ T cells by modulating the expression of T-box transcription factors. | Q42217866 | ||
| HIV-1 Tat: Its Dependence on Host Factors is Crystal Clear | Q42767857 | ||
| The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters | Q43671904 | ||
| Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243). | Q43967379 | ||
| The trans-activator gene of the human T cell lymphotropic virus type III is required for replication | Q44579665 | ||
| Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection | Q44674538 | ||
| Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis | Q44843305 | ||
| Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). | Q45012988 | ||
| HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection | Q45341243 | ||
| Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein. | Q45360139 | ||
| Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans | Q45710857 | ||
| Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection | Q45732713 | ||
| SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. | Q45739668 | ||
| Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. | Q45761033 | ||
| Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation-independent mechanism which requires binding of Tat to viral particles | Q45887444 | ||
| Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients | Q47216468 | ||
| Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. | Q51828622 | ||
| Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. | Q51926211 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | S13-29 | |
| P577 | publication date | 2015-06-22 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine | |
| P478 | volume | 15 Suppl 1 |
| Q92906228 | Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease |
| Q26764851 | Approaches to preventative and therapeutic HIV vaccines |
| Q40040813 | Formulation of chitosan with the polyepitope HIV-1 protein candidate vaccine efficiently boosts cellular immune responses in mice |
| Q36109585 | HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology |
| Q36986644 | HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial |
| Q33725630 | PKC-δ isoform plays a crucial role in Tat-TLR4 signalling pathway to activate NF-κB and CXCL8 production |
| Q38850174 | Reduced Frequency of Cells Latently Infected with Replication-Competent HIV-1 in Virally Suppressed Individuals Living in Rakai, Uganda |
Search more.